Martorell

Researchers are evaluating whether ultrasound-guided alcohol sclerotherapy can reduce pelvic pain and improve quality of life in women aged 18 to 45 diagnosed with ovarian endometriomas. This study compares sclerotherapy to expectant management to determine which approach better helps manage symptoms and quality of life impacts associated with this common form of endometriosis. Participants are randomly assigned to either receive ultrasound-guided alcohol sclerotherapy involving puncture and alcohol treatment of the cysts or to be managed expectantly with standard pain management if needed. The sclerotherapy procedure involves a 15-minute application of absolute ethanol followed by a wash. Both groups will be followed for six months, with assessments at baseline and 6 months post-treatment. During the study, participants will complete quality of life and pain assessments using standardized tools, provide blood and urine samples for biomarker analysis, and undergo ovarian reserve evaluations. Researchers will monitor adverse events, cyst recurrence, fertility outcomes, and healthcare costs. Pregnancy outcomes will be followed for an average of two years. The main outcome is quality of life measured at baseline and 6 months.

This research aims to identify individuals who may be eligible for interventional studies related to Alzheimers Disease by assessing specific biomarkers and cognitive performance. It is a Phase 3 screening study sponsored by Hoffmann-La Roche designed to evaluate potential participants using blood tests and cognitive assessments. The study focuses on adults aged 50 to 90 years to find candidates for further Alzheimers disease research. Participants will not receive any treatment but will undergo blood draws to measure the concentration of the biomarker pTau217. They will also complete the International Shopping List Test ISLT to assess cognitive function. This screening process helps determine eligibility for linked interventional Alzheimers disease studies by combining biomarker and cognitive data. During the study, participants will provide blood samples and perform cognitive tests at the initial visit. Researchers will measure the pTau217 levels in blood and record cognitive scores from the ISLT. The study involves no experimental treatment, focusing solely on assessment. Participation lasts until the primary completion date, with data collected on Day 1 to evaluate potential eligibility for further trials.

Researchers are evaluating the addition of immunotherapy drugs atezolizumab and tiragolumab to the standard chemoradiotherapy treatment for patients with localized squamous cell carcinoma of the anal canal. This Phase II, single-arm trial aims to improve the rate of clinical complete response, which means disappearance of all tumor lesions without residual disease, at the end of the consolidation treatment phase. The study also explores safety, quality of life, and molecular biomarkers to better understand treatment effects and outcomes. All participants will receive atezolizumab 1200 mg plus tiragolumab 600 mg for two cycles every three weeks alongside six weeks of standard chemoradiotherapy, which includes cisplatin, 5-Fluorouracil, and radiotherapy. After this concurrent phase, patients enter a consolidation phase receiving atezolizumab and tiragolumab for up to 24 weeks. Treatment will stop if the cancer progresses, unacceptable side effects occur, or based on patient or physician decision. Participants will be closely monitored throughout the study with clinical evaluations, biopsies to assess tumor response, and quality of life questionnaires. Researchers will track survival rates, tumor relapse, adverse events, and health-related quality of life over several years. Blood and tumor samples will be collected to study immune markers and genetic features. The total study duration for each participant includes treatment and long-term follow-up of up to five years.